Antiven

United Kingdom Founded: 2023 • Age: 3 yrs
Antiven creates innovative vaccines for snake bite treatment using biotechnology and proteomics.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 1 Services tracked
Competitors 11 Brand Intelligence

About Antiven

Antiven is a company based in United Kingdom founded in 2023. It operates as a B2B. Antiven offers products and services including Lyophilised Vaccine. Antiven operates in a competitive market with competitors including Biological E, Altimmune, Vaxart, Allergy Therapeutics and Medicago, among others.

  • Headquarter United Kingdom
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Antiven Private Limited
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Antiven

Antiven offers a comprehensive portfolio of products and services, including Lyophilised Vaccine.

Product name locked
Category locked
Primary

Thermostable polyvalent vaccine for treating snake bite envenomation in humans and animals.

Funding Insights of Antiven

Premium access

Detailed funding history for Antiven

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Antiven

Investments
Premium access

Investment portfolio details for Antiven

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Antiven

Premium access

Detailed financials for Antiven

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Antiven Comparisons

Antiven Primary company
Description
Antiven creates innovative vaccines for snake bite treatment...
Location
United Kingdom
Founded Year
2023
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Antiven

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Antiven

Antiven operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Altimmune, Vaxart, Allergy Therapeutics and Medicago, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Vaccines and therapeutics for multiple diseases are developed and marketed.
Locked Locked Locked
Vaccines for infectious diseases and solid tumors are developed.
Locked Locked Locked
Developer of therapeutic solutions for treating multiple infectious diseases
Locked Locked Locked
Aluminum-free allergy vaccines and diagnostics are developed for treatment.
Locked Locked Locked
Developer of vaccines to treat pandemic and seasonal influenza
Locked Locked Locked
Cancer vaccines using immune redirection are developed.
Premium access

Detailed competitors of Antiven

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Antiven

Premium access

Complete news archive for Antiven

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Antiven

Antiven was founded in 2023.

Antiven is headquartered in United Kingdom.

Antiven is a vaccine development company that utilizes biotechnology and proteomics to produce thermostable, polyvalent vaccines for snake bite envenomation. It focuses on saving lives, reducing poverty, and improving access to treatments in remote areas, including for livestock. The company conducts patented research and is registered in England, with leadership from experts trained internationally.

Antiven's top competitors include Biological E, Vaxart and Allergy Therapeutics.

Antiven offers Lyophilised Vaccine.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available